tiprankstipranks
Advertisement
Advertisement

HK:1541 Stock Latest News

ImmuneOnco Sets August Board Meeting to Approve Interim Results and Mull Dividend
Company AnnouncementsImmuneOnco Sets August Board Meeting to Approve Interim Results and Mull Dividend
2h ago
1541
ImmuneOnco Boosts Metabolic and Rare Disease Subsidiary with RMB50 Million Capital Injection
PremiumCompany Announcements
ImmuneOnco Boosts Metabolic and Rare Disease Subsidiary with RMB50 Million Capital Injection
8d ago
1541
ImmuneOnco Details ESOP-Linked Capital Increase at Non-Oncology Subsidiary
PremiumCompany Announcements
ImmuneOnco Details ESOP-Linked Capital Increase at Non-Oncology Subsidiary
14d ago
1541
ImmuneOnco Starts Phase II/III Trial of First-in-Class IMM0306 for IgG4-Related Disease
PremiumCompany Announcements
ImmuneOnco Starts Phase II/III Trial of First-in-Class IMM0306 for IgG4-Related Disease
1M ago
1541
ImmuneOnco flagged by HKEX over shareholder loan compliance
PremiumCompany Announcements
ImmuneOnco flagged by HKEX over shareholder loan compliance
1M ago
1541
ImmuneOnco Dilutes Stake in Subsidiary via De Minimis Connected Capital Injection
PremiumCompany AnnouncementsImmuneOnco Dilutes Stake in Subsidiary via De Minimis Connected Capital Injection
2M ago
1541
ImmuneOnco Deploys HK$87.5 Million Into Vital Ventures Cash Management Funds
Premium
Company Announcements
ImmuneOnco Deploys HK$87.5 Million Into Vital Ventures Cash Management Funds
2M ago
1541
ImmuneOnco plans on-market H-share buyback to signal confidence and boost value
Premium
Company Announcements
ImmuneOnco plans on-market H-share buyback to signal confidence and boost value
2M ago
1541
ImmuneOnco Shareholders Approve All AGM Resolutions and Grant New Capital Mandates
PremiumCompany Announcements
ImmuneOnco Shareholders Approve All AGM Resolutions and Grant New Capital Mandates
3M ago
1541
ImmuneOnco Rotates HK$205m Wealth Product Into Larger HK$212m Placement
PremiumCompany Announcements
ImmuneOnco Rotates HK$205m Wealth Product Into Larger HK$212m Placement
3M ago
1541
ImmuneOnco Begins Phase II Trial of First-in-Class CD47/CD20 Bispecific IMM0306 for Lupus
PremiumCompany Announcements
ImmuneOnco Begins Phase II Trial of First-in-Class CD47/CD20 Bispecific IMM0306 for Lupus
3M ago
1541
ImmuneOnco Sets 2026 AGM to Approve Results, Profit Plan and Share Issuance Mandate
PremiumCompany Announcements
ImmuneOnco Sets 2026 AGM to Approve Results, Profit Plan and Share Issuance Mandate
4M ago
1541
ImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma
PremiumCompany AnnouncementsImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma
5M ago
1541
ImmuneOnco Advances Timdarpacept to Phase III After Strong Leukemia Trial Data
Premium
Company Announcements
ImmuneOnco Advances Timdarpacept to Phase III After Strong Leukemia Trial Data
5M ago
1541
ImmuneOnco Completes Key Patient Enrollment in Phase III Trial of Lead Cancer Drug IMM01
Premium
Company Announcements
ImmuneOnco Completes Key Patient Enrollment in Phase III Trial of Lead Cancer Drug IMM01
5M ago
1541
ImmuneOnco Sets March 2026 Board Meeting to Approve 2025 Annual Results
PremiumCompany Announcements
ImmuneOnco Sets March 2026 Board Meeting to Approve 2025 Annual Results
5M ago
1541
ImmuneOnco Wins NMPA IND Nod for New Lupus Candidate Amid Share Price Swings
PremiumCompany Announcements
ImmuneOnco Wins NMPA IND Nod for New Lupus Candidate Amid Share Price Swings
5M ago
1541
ImmuneOnco Grants Connected Loan to Chairman for Tax Compliance Needs
PremiumCompany Announcements
ImmuneOnco Grants Connected Loan to Chairman for Tax Compliance Needs
6M ago
1541
ImmuneOnco Nears Interim Milestone in Phase III Trial of Lead CD47 Drug IMM01
PremiumCompany Announcements
ImmuneOnco Nears Interim Milestone in Phase III Trial of Lead CD47 Drug IMM01
7M ago
1541
ImmuneOnco Wins NMPA Nod to Test Lead CD47 Drug IMM01 in Atherosclerosis
PremiumCompany AnnouncementsImmuneOnco Wins NMPA Nod to Test Lead CD47 Drug IMM01 in Atherosclerosis
7M ago
1541
ImmuneOnco Reclaims Global Rights to Key Immuno-Oncology Assets IMM2510 and IMM27M
Premium
Company Announcements
ImmuneOnco Reclaims Global Rights to Key Immuno-Oncology Assets IMM2510 and IMM27M
7M ago
1541
ImmuneOnco CEO Increases Stake, Signaling Confidence in Growth
Premium
Company Announcements
ImmuneOnco CEO Increases Stake, Signaling Confidence in Growth
8M ago
1541

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >